
Heart Failure
Latest News
Latest Videos

CME Content
More News

A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.

Muthiah Vaduganathan, MD, MPH, and Javed Butler, MD, MPH, MBA, share approaches to treating patients with heart failure, focusing on patient education as well as social determinants of health.

Experts in cardiology review the classification of heart failure using left ventricle ejection fraction (EF).

On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.

Muthiah Vaduganathan, MD, MPH, comments on the impact of recurrent rehospitalizations for heart failure on survival.

Javed Butler, MD, MPH, MBA, and Robert J. Mentz, MD, review the current prevalence of heart failure in the US and Europe, as well as the clinical and economic challenges that arise with increasing prevalence.

At the 7th Annual Heart in Diabetes meeting, Joseph discussed the need to advance equity in diabetes management, from clinical practice to community-based interventions.

Stephen Greene, MD, discusses the results of a recent GWTG-HF registry analysis, which concluded just 1 in 5 hospitalized patients with HFrEF were discharged with an SGLT2 inhibitor prescription and less than 10% were receiving all 4 classes of guideline-directed medical therapy.

Steve Greene, MD, discusses the results of a TRANSFORM-HF analysis comparing the effects of furosemide and torsemide on quality of life outcomes in patients with heart failure.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

An analysis of Medicaid data from adults in Alabama suggests just more than 50% of patients fail to get ambulatory follow-up care within the recommended 14-day window following a first-time heart failure hospitalization.

Improved symptoms in 3 men with heart failure caused by ATTR-CM were confirmed by cardiovascular magnetic resonance scans showing the build-up of amyloid proteins had cleared.

12-month adherence to GLP1-RA or SGLT2i therapies was highest among individuals with T2D and/or heart failure with a low prescription co-payment.

Announced in a release by Daiichi Sankyo, Inc. and American Regent, Inc., the therapy is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.

Scott Solomon, MD, of Brigham and Women's Hospital, discusses how baseline patient characteristics inform what cardiologists might learn from the FINEARTS-HF trial, which he presented at Heart Failure 2023.

Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.

The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.

A posthoc analysis of the EMPEROR-Preserved trial suggested empagliflozin decreased the risk of heart failure hospitalization or cardiovascular death, regardless of background diuretic status.

Ahead of the May 27, 2023 PDUFA date, the HCPLive Cardiology editorial team spoke to a group of cardiologists to capture their perspective of the potential role of sotagliflozin.

An analysis of cost-effectiveness using data from SOLOIST-WHF provides insight into the varying cost-effectiveness of the agent as a treatment for worsening heart failure.

Muthiah Vaduganathan, MD, MPH, offers perspective on data from the PARAGLIDE-HF trial as well as a pooled analysis of data from the PARAGLIDE-HF and PARAGON-HF trials.

Presented at ESC HFA 2023, results of PARAGLIDE-HF detail the effects of sacubitril/valsartan on NT-proBNP and multiple clinical outcomes, relative to valsartan alone, in patients with HFmrEF or HFpEF.

In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.

Announced just more than a year after AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular death and HF hospitalizations for dapagliflozin based on results of the phase 3 DELIVER trial.

Each month, our editorial staff compiles a recap of the top news in cardiology from the past month. Our April 2023 month in review features new data and documents related to heart failure management, recaps and forecasts of top regulatory decisions, and other top news!































































